Find a study

📍 AllerVie Clinical Research · Birmingham, AL · +36 more US sites · Get directions →

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

📍 Digestive Health Specialists · Dothan, AL · +36 more US sites · Get directions →

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.

📍 Kailera Clinical Site · Cullman, AL · +34 more US sites · Get directions →

The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)

📍 Medical Dermatology Specialists · Phoenix, AZ · +39 more US sites · Get directions →

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

📍 Digestive Health Specialists · Dothan, AL · +34 more US sites · Get directions →

The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.

📍 MFA Clinical Research · Tuscaloosa, AL · +39 more US sites · Get directions →

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.

📍 Pinnacle Research Group · Anniston, AL · +30 more US sites · Get directions →

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

📍 The Institute for Liver Health II dba Arizona Clinical Trials - Mesa · Chandler, AZ · +39 more US sites · Get directions →

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

📍 Neighborhood Healthcare · Escondido, CA · +33 more US sites · Get directions →

This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study.

📍 AMR Clinical · Mobile, AL · +37 more US sites · Get directions →

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain.

📍 Applied Research Center Of Arkansas /ID# 268547 · Little Rock, AR · +29 more US sites · Get directions →

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment.

📍 Kailera Clinical Site · Glendale, AZ · +26 more US sites · Get directions →

The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

📍 The Institute for Liver Health II dba Arizona Clinical Trials - Mesa · Chandler, AZ · +39 more US sites · Get directions →

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs.

📍 Kailera Clinical Site · Anniston, AL · +22 more US sites · Get directions →

The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

📍 AllerVie Clinical Research · Birmingham, AL · +32 more US sites · Get directions →

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

📍 Birmingham Clinical Research · Birmingham, AL · +39 more US sites · Get directions →

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

📍 Cullman Clinical Trials · Cullman, AL · +22 more US sites · Get directions →

The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2.

📍 Lakeview Clinical Research · Guntersville, AL · +33 more US sites · Get directions →

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).

📍 Birmingham Clinical Research · Birmingham, AL · +39 more US sites · Get directions →

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

📍 Arizona Clinical Trials-Chandler · Chandler, AZ · +39 more US sites · Get directions →

This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).

📍 Cahaba Research, Inc. · Pelham, AL · +39 more US sites · Get directions →

Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.

📍 Headlands Research · Scottsdale, AZ · +35 more US sites · Get directions →

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks.

📍 Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute · Phoenix, AZ · +39 more US sites · Get directions →

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

📍 Investigational Site · Fountain Valley, CA · +21 more US sites · Get directions →

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.

📍 Arizona Liver Health - Chandler · Chandler, AZ · +30 more US sites · Get directions →

Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also asse

📍 Children's Hospital Los Angeles · Los Angeles, CA · +19 more US sites · Get directions →

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL.

📍 Arizona Research Center, Inc. · Phoenix, AZ · +18 more US sites · Get directions →

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week.

📍 MD First Research - Chandler · Chandler, AZ · +24 more US sites · Get directions →

The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.

📍 Cahaba Research, Inc. - Trussville Location · Birmingham, AL · +18 more US sites · Get directions →

This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more and at least 1 health problem related to their weight. People who have previously not managed to lose weight by changing their diet can participate.

📍 AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale · Avondale, AZ · +39 more US sites · Get directions →

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

📍 Neighborhood Healthcare · Escondido, CA · +18 more US sites · Get directions →

This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week.

📍 South Broward Research LLC · Miramar, FL · +21 more US sites · Get directions →

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.

📍 Carey Chronis MD Pediatric, Infant and Adolescent Medicine · Ventura, CA · +15 more US sites · Get directions →

The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

📍 Arizona Liver Health · Chandler, AZ · +39 more US sites · Get directions →

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.

📍 Kailera Clinical Site · Chandler, AZ · +22 more US sites · Get directions →

The primary objective of this study is to determine the efficacy of oral KAI-7535 once daily compared with placebo on percent change in body weight in participants living with obesity or overweight, with at least 1 weight-related comorbidity, without diabetes mellitus. Efficacy in participants with type 2 diabetes mellitus will be evaluated.

📍 CenExel Anaheim Clinical Trials · Anaheim, CA · +39 more US sites · Get directions →

The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight.

📍 Carey Chronis MD Pediatric, Infant and Adolescent Medicine · Ventura, CA · +13 more US sites · Get directions →

The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.

📍 Novartis Investigative Site · Birmingham, AL · +21 more US sites · Get directions →

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

📍 Allervie Clinical Research · Birmingham, AL · +39 more US sites · Get directions →

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.

📍 Enveda Investigative Site · Birmingham, AL · +22 more US sites · Get directions →

The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294 Participants will: * Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug * Return to the clinic for the final study visit at approximately week 16

📍 Dignity Health, Mercy Gilbert · Gilbert, AZ · +19 more US sites · Get directions →

This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week.

📍 Pinnacle Research Group LLC · Anniston, AL · +12 more US sites · Get directions →

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.

📍 Uni of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants.

📍 Arizona Liver Health · Chandler, AZ · +39 more US sites · Get directions →

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).

📍 Atd002 52021 · Oceanside, CA · +19 more US sites · Get directions →

The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

📍 Inmagene Site 1 · Lancaster, CA · +14 more US sites · Get directions →

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

📍 University of California San Diego · La Jolla, CA · +15 more US sites · Get directions →

A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH.

📍 Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC · Gilbert, AZ · +25 more US sites · Get directions →

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

📍 Leo Pharma Investigational site · Birmingham, AL · +14 more US sites · Get directions →

The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life.

📍 GSK Investigational Site · Chandler, AZ · +29 more US sites · Get directions →

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

📍 ImmuniMet, LLC · Modesto, CA · +18 more US sites · Get directions →

The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight.

📍 DM Clinical Research - Phoenix · Phoenix, AZ · +13 more US sites · Get directions →

The primary objective of this study is to assess the effect of enobosarm on total body weight

📍 Artemis Insitute for Clin Res · San Diego, CA · +16 more US sites · Get directions →

This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the skin once a week.

📍 Univ of Alabama Birmingham · Birmingham, AL · +14 more US sites · Get directions →

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week.

📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →

This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

📍 Valley Clinical Trials · Northridge, CA · +12 more US sites · Get directions →

This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

📍 Children's Hospital Los Angeles · Los Angeles, CA · +13 more US sites · Get directions →

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.

📍 Akero Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.

📍 Cahaba Dermatology & Skin Health Center /ID# 263855 · Birmingham, AL · +39 more US sites · Get directions →

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment.